• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当代 DES 植入术后患者靶病变失败的发生率及预测因素——来自 6 项随机对照试验的个体患者数据汇总分析。

Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.

机构信息

Clinical Trials Center, Cardiovascular Research Foundation, New York, NY.

Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY.

出版信息

Am Heart J. 2019 Jul;213:105-111. doi: 10.1016/j.ahj.2019.03.011. Epub 2019 Apr 12.

DOI:10.1016/j.ahj.2019.03.011
PMID:31132582
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7051011/
Abstract

BACKGROUND

Drug-eluting stents (DESs) have improved clinical outcomes of patients undergoing percutaneous coronary intervention (PCI). Nevertheless, adverse events related to previously treated lesion still occur. We sought to evaluate the incidence and predictors of target lesion failure (TLF) in patients undergoing contemporary DES implantation.

METHODS

Patient-level data from 6 prospective, randomized trials were pooled, and DES treatment outcomes were analyzed at up to 5 years. Primary outcome was TLF (cardiac death, target lesion revascularization, or target vessel myocardial infarction). Cox proportional-hazards model was used to identify predictors of TLF.

RESULTS

Overall, 10,072 patients were included in the analysis. TLF rate was 1.7%, 4.3%, and 11.9% at 30 days, 1 year, and 5 years, respectively. The only independent predictor of TLF at 30 days was stent length (hazard ratio [HR] 1.017, 95% CI 1.011-1.024, P < .0001). Moderate/severe calcification, stent length and post procedural diameter sthenosis were predictors between 30 days to 1 year but not at 1 to 5 years. Reference vessel diameter was the only lesion-related predictor at 5 years (P = .003). Clinical predictors of TLF between 30 days and 1 year were diabetes and hypertension (P < .01 for both), and between 1 and 5 years, diabetes (HR 1.40, 95% CI 1.13-1.73, P = .002), prior coronary artery bypass grafting (HR 2.52, 95% CI 1.92-3.30, P < .0001), and prior PCI (HR 1.29, 95% CI 1.02-1.64, P = .04) predicted TLF.

CONCLUSIONS

Predictors of TLF vary in the early, late, and very late postprocedural periods. Reference vessel diameter was the only lesion-related predictor of long-term TLF; clinical predictors were diabetes, prior coronary artery bypass grafting, and prior PCI.

摘要

背景

药物洗脱支架(DES)改善了经皮冠状动脉介入治疗(PCI)患者的临床结局。然而,与先前治疗的病变相关的不良事件仍会发生。我们旨在评估接受当代 DES 植入术的患者的靶病变失败(TLF)的发生率和预测因素。

方法

汇总了 6 项前瞻性随机试验的患者水平数据,并在最长 5 年时分析 DES 治疗结局。主要结局为 TLF(心脏死亡、靶病变血运重建或靶血管心肌梗死)。采用 Cox 比例风险模型确定 TLF 的预测因素。

结果

总体而言,纳入了 10072 例患者。30 天、1 年和 5 年时 TLF 发生率分别为 1.7%、4.3%和 11.9%。30 天时 TLF 的唯一独立预测因素是支架长度(风险比 [HR] 1.017,95%CI 1.011-1.024,P<.0001)。中重度钙化、支架长度和术后直径狭窄是 30 天至 1 年之间的预测因素,但不是 1 至 5 年之间的预测因素。参考血管直径是 5 年时唯一与病变相关的预测因素(P=.003)。30 天至 1 年时 TLF 的临床预测因素是糖尿病和高血压(均 P<.01),而 1 至 5 年时,糖尿病(HR 1.40,95%CI 1.13-1.73,P=.002)、先前的冠状动脉旁路移植术(HR 2.52,95%CI 1.92-3.30,P<.0001)和先前的 PCI(HR 1.29,95%CI 1.02-1.64,P=.04)预测了 TLF。

结论

TLF 的预测因素在早期、晚期和极晚期的术后期间有所不同。参考血管直径是长期 TLF 的唯一与病变相关的预测因素;临床预测因素是糖尿病、先前的冠状动脉旁路移植术和先前的 PCI。

相似文献

1
Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.当代 DES 植入术后患者靶病变失败的发生率及预测因素——来自 6 项随机对照试验的个体患者数据汇总分析。
Am Heart J. 2019 Jul;213:105-111. doi: 10.1016/j.ahj.2019.03.011. Epub 2019 Apr 12.
2
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).在冠状动脉疾病中,依维莫司洗脱支架与紫杉醇洗脱支架的荟萃分析:SPIRIT 临床试验计划的最终 3 年结果(在治疗新发病变的患者中,使用依维莫司洗脱冠状动脉支架系统治疗的西里斯 V 依维莫司洗脱冠状动脉支架系统的临床评估)。
JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.
3
Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.药物涂层支架治疗支架内再狭窄患者的临床结果:一项汇总分析的 2 年结果。
JACC Cardiovasc Interv. 2013 Sep;6(9):905-13. doi: 10.1016/j.jcin.2013.04.017. Epub 2013 Aug 14.
4
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).SPIRIT III 试验的 5 年随机对照研究结果:依维莫司洗脱 XIENCE V 支架与紫杉醇洗脱 Taxus 支架的比较——治疗初发的 native 冠状动脉病变患者的 XIENCE V 依维莫司洗脱冠状动脉支架系统的临床评估。
JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.
5
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.经皮冠状动脉介入治疗后病变长度和血管大小对临床结局的影响:来自 SPIRIT(依维莫司洗脱冠状动脉支架系统 XIENCE V 的临床评估)和 COMPARE(真实世界中第二代依维莫司洗脱和紫杉醇洗脱支架)随机试验的汇总分析。
JACC Cardiovasc Interv. 2011 Nov;4(11):1209-15. doi: 10.1016/j.jcin.2011.07.016.
6
[Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 5-year results of the TARGET Ⅱ trial].[一种新型腔内凹槽填充可生物降解聚合物西罗莫司洗脱支架治疗初发冠状动脉病变的安全性和有效性:TARGETⅡ试验5年结果]
Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Jul 24;46(7):523-528. doi: 10.3760/cma.j.issn.0253-3758.2018.07.004.
7
The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.SYNTAX 评分对依维莫司和佐他莫司洗脱支架血运重建后 1 年结局的预后价值:RESOLUTE 所有患者试验的一项亚组研究。
JACC Cardiovasc Interv. 2011 Apr;4(4):432-41. doi: 10.1016/j.jcin.2011.01.008.
8
Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.依维莫司洗脱支架经皮冠状动脉介入治疗患者:XIENCE V 依维莫司洗脱冠状动脉支架系统治疗初发冠状动脉病变患者的临床评价试验的最终 3 年结果。
Am Heart J. 2013 Dec;166(6):1035-42. doi: 10.1016/j.ahj.2013.08.030. Epub 2013 Oct 31.
9
Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.新一代药物洗脱支架与药物洗脱球囊治疗支架内再狭窄的疗效比较:韩国多中心支架内再狭窄登记研究的患者水平汇总分析。
Int J Cardiol. 2017 Mar 1;230:181-190. doi: 10.1016/j.ijcard.2016.12.176. Epub 2016 Dec 29.
10
Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.依维莫司洗脱支架用于裸金属和药物洗脱支架内再狭窄患者:RIBS IV和V试验患者水平汇总分析结果
Circ Cardiovasc Interv. 2016 Jul;9(7). doi: 10.1161/CIRCINTERVENTIONS.115.003479.

引用本文的文献

1
Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.用于冠状动脉疾病的药物涂层球囊:从理论到实践
Curr Treat Options Cardiovasc Med. 2025 Dec;27(1). doi: 10.1007/s11936-025-01084-4. Epub 2025 Mar 19.
2
Drug-Coated Balloons for Coronary Interventions: A Focused Review.用于冠状动脉介入治疗的药物涂层球囊:聚焦综述
Methodist Debakey Cardiovasc J. 2025 Aug 12;21(4):37-53. doi: 10.14797/mdcvj.1607. eCollection 2025.
3
Impact of Diabetes on Long-Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions.

本文引用的文献

1
Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus.无聚合物涂层 Amphilimus 洗脱支架与生物可降解聚合物涂层 Biolimus 洗脱支架在伴或不伴糖尿病患者中的应用。
Int J Cardiol. 2017 Oct 15;245:69-76. doi: 10.1016/j.ijcard.2017.06.028.
2
Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis).冠状动脉疾病患者中利达莫司洗脱冠状动脉支架与佐他莫司洗脱冠状动脉支架的随机对照比较:BIONICS试验(冠状动脉狭窄中BioNIR利达莫司洗脱冠状动脉支架系统)的主要结果
Circulation. 2017 Oct 3;136(14):1304-1314. doi: 10.1161/CIRCULATIONAHA.117.028885. Epub 2017 Aug 9.
3
糖尿病对冠状动脉分叉病变经皮冠状动脉介入治疗长期预后的影响。
Catheter Cardiovasc Interv. 2025 Aug;106(2):743-751. doi: 10.1002/ccd.31476. Epub 2025 Mar 5.
4
Drug coated balloon angioplasty for de novo coronary lesions in large vessels: a systematic review and meta-analysis.药物涂层球囊血管成形术治疗大血管新发冠状动脉病变:一项系统评价和荟萃分析。
Sci Rep. 2025 Feb 10;15(1):4921. doi: 10.1038/s41598-025-85734-4.
5
A novel biodegradable polymer-coated sirolimus-eluting stent: 1-year results of the HELIOS registry.一种新型可生物降解聚合物涂层西罗莫司洗脱支架:HELIOS 注册研究的 1 年结果。
Chin Med J (Engl). 2023 Aug 5;136(15):1848-1854. doi: 10.1097/CM9.0000000000002324.
6
Five-year clinical outcomes of a 2.25 mm sirolimus-eluting stent in Japanese patients with very small coronary artery disease: final results of the CENTURY JSV study.CENTURY JSV 研究:在日本小血管病变患者中应用 2.25mm 西罗莫司洗脱支架的 5 年临床结果。
Cardiovasc Interv Ther. 2023 Apr;38(2):194-201. doi: 10.1007/s12928-022-00890-y. Epub 2022 Sep 2.
7
Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease.药物涂层球囊治疗冠状动脉疾病的中期临床结果
J Clin Med. 2022 Mar 27;11(7):1859. doi: 10.3390/jcm11071859.
8
Intravascular Lithotripsy in Calcified Coronary Lesions: A Single-Center Experience in "Real-World" Patients.钙化冠状动脉病变的血管内碎石术:“真实世界”患者的单中心经验
Front Cardiovasc Med. 2022 Feb 21;9:829117. doi: 10.3389/fcvm.2022.829117. eCollection 2022.
9
Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry.2481 例未经选择的真实世界患者使用无聚合物西罗莫司洗脱支架治疗的临床结果:NANO 多中心注册研究的 3 年结果。
BMC Cardiovasc Disord. 2021 Nov 12;21(1):537. doi: 10.1186/s12872-021-02356-0.
10
Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者支架内再狭窄风险预测列线图的建立与验证。
BMC Cardiovasc Disord. 2021 Sep 14;21(1):435. doi: 10.1186/s12872-021-02255-4.
Comparison of two biodegradable-polymer-based sirolimus-eluting stents with varying elution and absorption kinetics in patients with acute myocardial infarction: A subgroup analysis of the PANDA III trial.急性心肌梗死患者中两种洗脱和吸收动力学不同的可生物降解聚合物西罗莫司洗脱支架的比较:PANDA III试验的亚组分析
Catheter Cardiovasc Interv. 2017 Mar;89(S1):520-527. doi: 10.1002/ccd.26918. Epub 2017 Jan 21.
4
Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial.基于可生物降解聚合物的西罗莫司洗脱支架,具有不同的洗脱和吸收动力学:PANDA III 试验。
J Am Coll Cardiol. 2016 May 17;67(19):2249-2258. doi: 10.1016/j.jacc.2016.03.475.
5
Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials.探讨糖尿病患者与非糖尿病患者中,冠状动脉病变复杂性对药物洗脱支架结局的影响:来自 18 项汇总随机试验的分析。
J Am Coll Cardiol. 2014 May 27;63(20):2111-2118. doi: 10.1016/j.jacc.2014.01.064. Epub 2014 Mar 13.
6
Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography.10004 例接受监测血管造影的患者冠状动脉支架置入术后再狭窄的发生率和预测因素。
Heart. 2014 Jan;100(2):153-9. doi: 10.1136/heartjnl-2013-304933. Epub 2013 Nov 22.
7
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).SPIRIT III 试验的 5 年随机对照研究结果:依维莫司洗脱 XIENCE V 支架与紫杉醇洗脱 Taxus 支架的比较——治疗初发的 native 冠状动脉病变患者的 XIENCE V 依维莫司洗脱冠状动脉支架系统的临床评估。
JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.
8
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.在所有需要经皮冠状动脉介入治疗的患者中(荷兰 PEERS 研究),第三代佐他莫司洗脱和依维莫司洗脱支架的应用:一项随机、单盲、多中心、非劣效性试验。
Lancet. 2014 Feb 1;383(9915):413-23. doi: 10.1016/S0140-6736(13)62037-1. Epub 2013 Oct 31.
9
The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.ENDEAVOR IV 试验的“最终”5 年随访结果,比较了依维莫司洗脱支架与紫杉醇洗脱支架。
JACC Cardiovasc Interv. 2013 Apr;6(4):325-33. doi: 10.1016/j.jcin.2012.12.123. Epub 2013 Mar 20.
10
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.无聚合物可降解聚合物雷帕霉素洗脱支架与持久性聚合物依维莫司洗脱支架(COMPARE II):一项随机、对照、非劣效性试验。
Lancet. 2013 Feb 23;381(9867):651-60. doi: 10.1016/S0140-6736(12)61852-2. Epub 2013 Jan 30.